Low

Point of Care Strep Tests Speed Treatment, Lower Costs

Beta-hemolytic group A streptococcus (S. pyogenes) is the most common bacterial agent associated with upper respiratory tract infections. Although it usually involves mild symptoms (such as headache, fever or abdominal pain) if left untreated streptococcal infection can worsen and become life-threatening. Early diagnosis and treatment of group A streptococcal pharyngitis has been shown to red...

Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal

Medical conventions are challenged every day. Already in the new year, the effectiveness of cold medicine and the gold standard in breast cancer treatment have been challenged. Standards in cholesterol testing are the latest casualty of medical innovation. For years, cholesterol has been measured by a simple panel o...

Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- ResponseGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - BiovestInternational, Inc. (OTCBB: BVTI), a majority owned subsidiary ofAccentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June27, 2007 blinded interim data from the start of its fast-trackedpivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin'slymphoma (NHL) from September 2000 through June 2006. This interimblinded dat...

New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging

Women Report Partner's Symptoms Negatively Affect Relationship BOCA RATON, Fla., June 25, 2007 /PRNewswire/ -- Results of a newnationwide survey show that more than half of women whose malepartners have symptoms of a medical condition known as lowtestosterone incorrectly attribute them to the normal course ofaging. The survey also found that, while women believe their malepartner's sympto...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking datapresented at the American Diabetes Association (ADA) 67th AnnualScientific Sessions showed that, when used investigationally asinitial therapy, JANUVIA(TM) (sitagliptin) in combination withmetformin provided significant glycemic improvement and wasgenerally well tolerated over 54 weeks in patients with type 2diabetes. Additional new...

Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -

DOYLESTOWN, Pa., June 20, 2007 /PRNewswire-FirstCall/ -- QuigleyPharma, <a target="_blank" href="http://www.quigleypharma.com/">www.QuigleyPharma.com , a whollyowned subsidiary of The Quigley Corporation announced today that ithas completed a follow-up study to evaluate the impact of QR-443 onlevels of a pro-inflammatory cytokine Interleukin-6 (IL-6) in acachexia model. This new data...

Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for Heart Failure

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 19, 2007 - GeronCorporation (Nasdaq: GERN) today reported that research documentingthe scalable production, survival following engraftment andpositive impact on cardiac function in infarcted rats was presentedtoday for GRNCM1, the company's human embryonic stem cell(hESC)-based therapeutic for heart failure, at the InternationalSociety for Stem Cell...

Treating Heart Disease Risk Factors May Slow Alzheimer's Disease Progression

- Late Life Weight Loss and "Motivational Reserve" May Also AffectAlzheimer's Risk - WASHINGTON, June 10, 2007 /PRNewswire-USNewswire/ -- A new studysuggests that treating risk factors for heart disease and stroke,such as high blood pressure and diabetes, may slow the progressionof Alzheimer's disease, according to research reported today at the2nd Alzheimer's Association International Co...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCOProceedings HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancerresearcher affiliated with the US Oncology Research Networkpresented findings from a randomized, multicenter phase III trialthat compared the disease-free survival (DFS) obtained with tworegimens of adjuvant therapy for patients with high-risk breastcancer. Th...

New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients

Aggrenox® (Asasantin® Retard) considered by many asfirst-line in secondary stroke prevention INGELHEIM, Germany, 31 May 2007 - New data presented today at the16th European Stroke Conference in Glasgow confirm that therapywith dipyridamole plus ASA (extended-release dipyridamole plus ASAis marketed as Aggrenox® or Asasantin® Retard) is superiorto ASA* alone in...

Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants

Study released at the Pediatric Academic Societies' Annual MeetingThis Month in Toronto Shows That Switching to Masimo SET PulseOximetry Technology Can Reduce the Risk Associated with ROP by 40% IRVINE, Calif., May 30, 2007 /PRNewswire/ -- Masimo, theinventor of Pulse CO-Oximetry and Read-Through Motion and LowPerfusion pulse oximetry, reported that a new independent studypresented at the...

Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up

Separate Survey Underscores Impact of Disease on Work Status andProductivity WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ -- Findingspresented today at Digestive Disease Week(R) 2007 (DDW), fromlong-term extensions of the ACT trials (Active Ulcerative Colitis 1& 2) show that subjects with moderately to severely activeulcerative colitis (UC) who had responded to REMICADE(R)(inflixi...

Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)

MALVERN, Pa., May 22, 2007 /PRNewswire-FirstCall/ -- AuxiliumPharmaceuticals, Inc. today announced that new data showimprovements in symptoms of decreased libido, energy levels anderectile function in 76 percent of hypogonadal men after switchingbrands of testosterone replacement gel therapy. Total testosteronelevels increased significantly in patients who switched toAuxilium's Testim(R)...

Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy

Data Also Show Nebivolol Lowers Blood Pressure in Obese andNon-Obese Hypertensive Patients CHICAGO, May 21, 2007 /PRNewswire-FirstCall/ -- ForestLaboratories, Inc. today presented positive data from two clinicalstudies and one pooled analysis of nebivolol, a selective beta1-blocker with vasodilating properties currently under review bythe U.S. Food and Drug Administration (FDA) for the tr...

Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers' Diarrhea Stimulates Immune Response Even at Low Doses

-- Data Gathered to Assist in Design of Future Trials, OtherPrograms -- GAITHERSBURG, Md. and LISBON, Portugal, April 26, 2007/PRNewswire-FirstCall/ -- Iomai Corporation today announced resultsfrom a 400-patient, Phase 2 dose-ranging trial of its patch-basedvaccine for travelers' diarrhea. The trial was conducted to assessthe ability of a range of vaccine doses to generate an immunerespo...

Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207 for BPH

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 18, 2007 - NymoxPharmaceutical Corporation (NASDAQ: NYMX) announced todaycompletion of a new 42 month follow-up study of NX-1207 for benignprostatic hyperplasia (BPH). The study evaluated symptomaticprogress of U.S. patients involved in the Company's two Phase 1-2studies initiated in 2003. Individuals in the study were assessedfor symptomatic im...

Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients

Encouraging Results Prompted Phase 2 Study Now Underway at NineCenters SAN DIEGO, Calif., April 16, 2007 /PRNewswire/ -- Ceregene,Inc., a biopharmaceutical company, today presented long termfollow-up data from a Phase 1 clinical trial of CERE-120, a genetherapy product in development for the treatment of Parkinson'sdisease, demonstrating a 36 percent (p<0.001) reduction inParkinson's sym...

Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying to Control It Later

LONDON, April 12, 2007--The costs of eradicatingpoliomyelitis from the remaining infected countries, while high inthe short term, are much lower than the long term costs of tryingto control infections without eradication. And a recently developedmonovalent vaccine is almost three times more effective againsttype 1 poliomyelitis than an existing trivalent vaccine. These are...

Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke

BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - InotekPharmaceuticals Corporation announced today the publication in thejournal Stroke of preclinical animal data showing that theadministration of a poly(ADP-Ribose) polymerase (PARP) inhibitorhas a large protective effect on the survival of certain braincells following a stroke. PARP is a nuclear enzyme that directs therepair of damaged DNA...

Low-Dose Steroid Combined With Lenalidomide Prolongs Survival Compared With High-Dose Steroid for Multiple Myeloma Treatment

WASHINGTON, April 4, 2007-Preliminary results from a large,randomized clinical trial for patients with newly diagnosedmultiple myeloma, a cancer typically found in bone marrow, hasshown that the use of a low dose of the steroid dexamethasone(Decadron ®), in combination with lenalidomide (Revlimid ®)is associated with improved survival when compared to a treatmentregimen with lenalid...

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery

Data to be Presented at the XXI Congress of the InternationalSociety on Thrombosis and Haemostasis SOUTH SAN FRANCISCO, Calif., April 04, 2007 /PRNewswire/ --Portola Pharmaceuticals, Inc. today announced that it has receivedpositive results from EXPERT, a Phase II study of its oral FactorXa inhibitor, PRT054021, for the prevention of venousthromboembolism (VTE) following total knee replac...

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma

SUMMIT, N.J., April 04, 2007 /PRNewswire-FirstCall/ -- CelgeneCorporation announced that the Eastern Cooperative Oncology Group(ECOG) has reported that its Data Monitoring Committee's (DMC)review of preliminary results from a large, randomized clinicaltrial for patients with newly diagnosed multiple myeloma has foundthat the use of a low dose of dexamethasone (Decadron) incombination wit...

Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show

NEW ORLEANS--(BUSINESS WIRE)--Mar 27, 2007 - Pfizer announced todaythat Lipitor(R) (atorvastatin calcium) Tablets (80 mg) loweredhospitalization costs by significantly reducing the risk ofcardiovascular events in patients with heart disease, according totwo separate economic analyses. The data were presented at theannual meeting of the American College of Cardiology. "One of these analyse...

CombinatoRx Provides Topline Results from Phase 2 RA Study with CRx-139 and Very Low Dose Prednisolone

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 26, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) today announced preliminary results ofa phase 2 clinical trial studying CRx-139 (a synergisticcombination of 3mg prednisolone and the antidepressant paroxetine)and 3mg prednisolone alone, in patients with rheumatoid arthritis(RA). This trial served two important purposes. One purpose was todetermine th...

Cholesterol Drug Fails to Slow Progression of Coronary Disease, Cleveland Clinic Study Reports

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- Cleveland Clinicresearchers today report that the drug torcetrapib, despite raisinghigh density lipoprotein cholesterol (HDL) or the "good"cholesterol by more than 60%, did not slow the progression ofplaque buildup in the coronary arteries as measured using anultrasound probe. Steven Nissen, M.D., Chairman of Cardiovascular Medicine atCl...

New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu

BASEL, Switzerland, March 20, 2007 -- Clinical studies haveshown (1) similar rates of neurologic and psychiatric events inpediatric influenza patients being treated with Tamiflu compared tothose receiving no treatment for their influenza. Furthermore,recent data derived from US health insurance records (2) between1999-2006 of over 101,000 influenza patients treated with Tamifluand over 2...

Framingham Study Shows Parents Who Live Long Pass On Lower Risk of Cardiovascular Disease

BETHESDA, Md., March 13, 2007--New evidence suggests that if youcould choose your parents, you could reduce your risk ofcardiovascular disease. Researchers from the long-standingFramingham Heart Study (FHS), a program of the National Heart,Lung, and Blood Institute (NHLBI) of the National Institutes ofHealth, report that people whose parents live longer were morelikely to avoid developing h...

IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation

Animal Data Shows Prolonged Survival AND Increased PlateletConcentrations SCOTTSDALE, Ariz., March 08, 2007 /PRNewswire-FirstCall/ --ImmuneRegen BioSciences, a wholly-owned subsidiary of IRBioSciences Holdings, Inc. announced today that ongoing analysis ofdata acquired from previously performed animal efficacy studies hasrevealed evidence that ImmuneRegen's developmental stage product,Ra...